Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system

Current Opinion in Neurology

Volumn 19, Issue 4, 2006, Pages 358-361

  Nath, Avindra ^a,b   Sacktor, Ned ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 509 Pathology ^*  (United States)

Author keywords

Antiretroviral drugs; Brain; Dementia; HAART; HIV; Immune reconstitution; Nerve

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

BRAIN; CENTRAL NERVOUS SYSTEM INFECTION; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; GENE TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE STATUS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGICAL COMPLICATION; NEUROPROTECTION; NONHUMAN; PERSISTENT VIRUS INFECTION; REVIEW; VIRUS REPLICATION;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; CENTRAL NERVOUS SYSTEM; HIV INFECTIONS; HUMANS; VIRUS REPLICATION;

EID: 33747335917     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000236614.51592.ca     Document Type: Review

References (29)

1. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 (Suppl. 2):115-121.
2. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4:543-555. A detailed review that discusses the epidemiology, clinical manifestations, pathophysiology and treatment of HIV dementia and neuropathy.
3. Clements JE, Babas T, Mankowski JL, et al. The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis 2002; 186:905-913.
4. McArthur JC, McDermott MP, McClernon D, et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004; 61:1687-1696.
5. Haughey NJ, Cutler RG, Tamara A, et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 2004; 55:257-267.
6. Turchan J, Sacktor N, Wojna V, et al. Neuroprotective therapy for HIV dementia. Curr HIV Res 2003; 1:373-383.
7. Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002; 186 (Suppl. 2):S193-S198.
8. Anthony IC, Ramage SN, Carnie FW, et al. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005; 64:529-536. This paper provides evidence for a clear neuropathological benefit of antiretroviral therapy.
9. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8:136-142.
10. Abdulle S, Hagberg L, Gisslen M. Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients. HIV Med 2005; 6:164-169.
11. Avison MJ, Nath A, Greene-Avison R, et al. Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol 2004; 10:223-232.
12. Srinivas RV, Middlemas D, Flynn P, Fridland A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998; 42:3157-3162.
13. Hayashi K, Pu H, Andras IE, et al. HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab 2005; doi: 10.1038/sj.jcbfm.9600254 [Epub ahead of print].
14. Owen A, Janneh O, Hartkoorn RC, et al. In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther 2005; 314:1202-1209. This study shows how novel strategies can be developed to enhance the delivery of antiretroviral compounds to the brain.
15. Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses 2005; 21:706-713.
16. Baeuerle M, Schmitt-Haendle M, Taubald A, et al. Severe HIV-1 encephalitis and development of cerebral non-Hodgkin lymphoma in a patient with persistent strong HIV-1 replication in the brain despite potent HAART - case report and review of the literature. Eur J Med Res 2005; 10:309-316.
17. Pfefferbaum A, Adalsteinsson E, Sullivan EV. Cortical NAA deficits in HIV infection without dementia: influence of alcoholism comorbidity. Neuropsychopharmacology 2005; 30:1392-1399.
18. Letendre SL, Cherner M, Ellis RJ, et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. Aids 2005; 19 (Suppl. 3):S72-S78.
19. Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004; 36:562-566.
20. Green DA, Masliah E, Vinters HV, et al. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. Aids 2005; 19:407-411.
21. Smit TK, Brew BJ, Tourtellotte W, et al. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 2004; 78:10133-10148.
22. Chang L, Ernst T, St Hillaire C, Conant K. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther 2004; 9:431-440.
23. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447-454.
24. Stoll M, Schmidt RE. Immune restoration inflammatory syndromes: apparently paradoxical clinical events after the initiation of HAART. Curr HIV/AIDS Rep 2004; 1:122-127.
25. Miller RF, Isaacson PG, Hall-Craggs M, et al. Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol (Berl) 2004; 108:17-23.
26. Capparelli EV, Holland D, Okamoto C, et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. Aids 2005; 19:949-952. This paper provides a rationale for the use of Lopinavir in patients at risk for HIV dementia.
27. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005; 293:2003-2011. This paper shows that modulation of host genes by existing Food and Drug Administration (FDA)-approved drugs can be used to prevent HIV replication.
28. Routy JP. Valproic acid: a potential role in treating latent HIV infection. Lancet 2005; 366:523-524.
29. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-555. This paper and the accompanying editorial demonstrate for the first time, although in a small number of patients, that it might be possible to impact the HIV reservoirs with drugs such as valproate when given in a setting of controlled antiretroviral therapy.